An observational study in Cardiovascular Diseases (CVD) and Cerebro Vascular Disease, sponsored by Samsung Medical Center. Recruiting at 1 site in South Korea. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by Samsung Medical Center · Observational
This study aims to establish a comprehensive, long-term clinical registry infrastructure for heart and brain vascular diseases (cardiovascular diseases and stroke) at Samsung Medical Center. In South Korea, these diseases are a leading cause of death, with a rapidly increasing burden due to an aging population and changing lifestyles. Despite this, there is a lack of large-scale, systematic data specifically focused on the long-term clinical course and unique characteristics of Korean patients.
The central hypothesis of this study is that the establishment of a standardized registry infrastructure-integrating both retrospective (historical) and prospective (future) data collection-will provide a more accurate and comprehensive understanding of the natural history and risk factors of heart and brain vascular diseases in the Korean population than currently available fragmented data. By combining existing medical records with ongoing patient follow-up, this infrastructure will serve as a critical scientific platform for developing personalized prevention and precision medicine strategies.
By building this organized data collection system, the study will:
Construct a robust infrastructure to collect uniform, high-quality clinical data, encompassing both past medical history (retrospective) and future clinical progress (prospective) from a large population of Korean patients.
Monitor long-term health outcomes and the progression of diseases by tracking patients over many years.
Analyze the interaction between various risk factors and patient outcomes to identify population-specific patterns.
Create a scalable platform that can integrate advanced technologies, such as multi-omics and digital health tools, for future research.
Ultimately, this integrated registry infrastructure is expected to provide the essential scientific evidence needed to optimize clinical guidelines and improve the long-term quality of life for patients with heart and brain vascular diseases in Korea.
4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.
This study's planned enrollment of 800,000 is above the median of 573 across 1,485 observational studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Samsung Medical Center is the lead sponsor of 980 studies on the registry; 146 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
The study population consists of patients diagnosed with or treated for heart and brain vascular diseases (cardiovascular diseases and stroke) at Samsung Medical Center, a tertiary academic hospital in Seoul, Korea.
This cohort includes:
Retrospective Group: Patients with clinical records within the hospital's historical database to analyze past clinical courses and long-term outcomes.
Prospective Group: Patients newly visiting or currently under follow-up care at the heart, stroke, and vascular centers who consent to long-term monitoring.
The population covers a wide clinical spectrum, from acute emergency cases (e.g., myocardial infarction, ischemic stroke) to chronic management.
A patient who visited Samsung Medical Center due to cardiovascular and cerebrovascular disease.
Exclusion Criteria:
A patient deemed unable to participate in the study based on the judgment of the medical staff.
Routine pharmacological treatments including antiplatelets, antihypertensives
Surgical or interventional procedures such as PCI (Percutaneous Coronary Intervention) or stent thrombectomy for stroke.
Habitual factors including smoking cessation, physical activity, and dietary habits monitored during the follow-up.
Incidence of Major Adverse Cardio-Cerebrovascular Events (MACCE)
Time frame: Up to 20 years (from the date of enrollment until the end of the follow-up period)
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Samsung Medical Center